CL2023003102A1 - Vectores aavrh74 para la terapia génica de las distrofias musculares. - Google Patents

Vectores aavrh74 para la terapia génica de las distrofias musculares.

Info

Publication number
CL2023003102A1
CL2023003102A1 CL2023003102A CL2023003102A CL2023003102A1 CL 2023003102 A1 CL2023003102 A1 CL 2023003102A1 CL 2023003102 A CL2023003102 A CL 2023003102A CL 2023003102 A CL2023003102 A CL 2023003102A CL 2023003102 A1 CL2023003102 A1 CL 2023003102A1
Authority
CL
Chile
Prior art keywords
gene therapy
muscular dystrophies
aavrh74
vectors
aavrh74 vectors
Prior art date
Application number
CL2023003102A
Other languages
English (en)
Spanish (es)
Inventor
Arun Srivastava
Keyun Qing
Barry John Byrne
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of CL2023003102A1 publication Critical patent/CL2023003102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
CL2023003102A 2021-04-23 2023-10-18 Vectores aavrh74 para la terapia génica de las distrofias musculares. CL2023003102A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179097P 2021-04-23 2021-04-23
US202263327410P 2022-04-05 2022-04-05

Publications (1)

Publication Number Publication Date
CL2023003102A1 true CL2023003102A1 (es) 2024-07-12

Family

ID=81648417

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003102A CL2023003102A1 (es) 2021-04-23 2023-10-18 Vectores aavrh74 para la terapia génica de las distrofias musculares.
CL2024002556A CL2024002556A1 (es) 2021-04-23 2024-08-27 Proteína de la cápsida de aavrh74; partícula de aavrh74; composición; y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024002556A CL2024002556A1 (es) 2021-04-23 2024-08-27 Proteína de la cápsida de aavrh74; partícula de aavrh74; composición; y su uso.

Country Status (13)

Country Link
US (2) US20240181083A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326857A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024514962A (cg-RX-API-DMAC7.html)
KR (1) KR20240000542A (cg-RX-API-DMAC7.html)
AU (1) AU2022262407A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021495A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217649A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023003102A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015911A2 (cg-RX-API-DMAC7.html)
IL (1) IL307881A (cg-RX-API-DMAC7.html)
MX (1) MX2023012509A (cg-RX-API-DMAC7.html)
TW (1) TW202304954A (cg-RX-API-DMAC7.html)
WO (1) WO2022226289A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US12358954B2 (en) 2012-05-15 2025-07-15 University Of Florida Research Foundation, Incorporated Capsid-modified rAAV vector compositions and methods therefor
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2024184781A1 (en) * 2023-03-03 2024-09-12 Universitat Heidelberg Engineered aav capsids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342886B2 (ja) * 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
EP3221456B1 (en) 2014-11-21 2021-09-22 University of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
JP7785352B2 (ja) * 2019-08-14 2025-12-15 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 遺伝子治療のためのaavカプシドバリアント

Also Published As

Publication number Publication date
US20220347317A1 (en) 2022-11-03
CO2023015911A2 (es) 2023-11-30
CL2024002556A1 (es) 2025-01-10
BR112023021495A2 (pt) 2023-12-19
WO2022226289A2 (en) 2022-10-27
KR20240000542A (ko) 2024-01-02
WO2022226289A3 (en) 2023-03-02
US20240181083A1 (en) 2024-06-06
TW202304954A (zh) 2023-02-01
EP4326857A2 (en) 2024-02-28
AU2022262407A9 (en) 2023-11-09
CA3217649A1 (en) 2022-10-27
MX2023012509A (es) 2024-01-03
IL307881A (en) 2023-12-01
AU2022262407A1 (en) 2023-10-26
JP2024514962A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
IL279918A (en) Gene therapy vectors for treatment of danon disease
IL285238A (en) Gene therapy vectors for treatment of danon disease
JP1747355S (ja) 筋肉マッサージ器
EP3746100A4 (en) GENE THERAPY FOR BELT MUSCULAR DYSTROPHY TYPE 2C
PT3858333T (pt) Preparação e armazenamento de formulações de arn lipossómico adequadas para terapia
IL262211A (en) Gene therapy for treating mucopolysaccharidosis type ii
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
EP4051324A4 (en) GENE THERAPY VECTORS
PT3827004T (pt) Derivados da 4-(1,3,4-oxadiazol-2-il)piridin-2(1h)-ona como inibidores da histona desacetilase 6 (hdac6) para o tratamento de infeções e.g.
IL307881A (en) AAVRH74 vectors for gene therapy in muscular dystrophy
EP4282481C0 (fr) Sequences siarn ciblant l'expression des genes jak1 humains pour une utilisation therapeutique
IL307604A (en) Adenoviral gene therapy vectors
JP1778652S (ja) マッサージ器
EP4267200A4 (en) ADENOVIRAL VECTORS FOR GENE THERAPY
IL325421A (en) Combinational treatment
EP4356127A4 (en) THERAPEUTIC OLIGONUCLEOTIDE METHODS
EP4294402A4 (en) THERAPEUTIC PROCEDURES
IL310017A (en) Retgc gene therapy
JP1778600S (ja) マッサージ器
EP4401756A4 (en) FRATAXIN GENE THERAPY
ES1218143Y (es) Fresa para el tratamiento de la perimplantitis
JP1747377S (ja) 筋肉マッサージ器
JP1743141S (ja) 筋肉マッサージ器
JP1709518S (ja) 筋肉マッサージ器
PL4216944T3 (pl) Nowa koncepcja terapii do leczenia infekcji korona, w szczególności infekcji COVID-19